|
08 Feb 2022 |
Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma
|
|
08 Feb 2022 |
Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer
|
|
04 Feb 2022 |
Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom
|
|
04 Feb 2022 |
AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease
|
|
03 Feb 2022 |
EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea
|
|
02 Feb 2022 |
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
|
|
01 Feb 2022 |
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
|
|
01 Feb 2022 |
Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine Candidate
|
|
01 Feb 2022 |
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
|
|
28 Jan 2022 |
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
|
|
27 Jan 2022 |
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
|
|
25 Jan 2022 |
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
|
|
25 Jan 2022 |
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
|
|
13 Jan 2022 |
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
|
|
13 Jan 2022 |
Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
|
|
07 Jan 2022 |
Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs
|
|
06 Jan 2022 |
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
|
|
05 Jan 2022 |
Leiden University Medical Center and Intravacc to Start Clinical Trial with New Intranasal Corona Vaccine
|
|
05 Jan 2022 |
Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
|
|
31 Dec 2021 |
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
|
|
28 Dec 2021 |
Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
|
|
23 Dec 2021 |
Vaxzevria significantly boosted antibody levels against Omicron
|
|
22 Dec 2021 |
AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
|
|
22 Dec 2021 |
Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
|
|
20 Dec 2021 |
European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
|
